Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Avenue Therapeutics Finalizes Agreement with FDA for IV Tramadol Phase 3 Safety Study
Details : AVE-901 (tramadol) inhibits serotonin reuptake and norepinephrine reuptake, enhancing inhibitory effects on pain transmission in the spinal cord. It is being developed for post-operative pain.
Product Name : AVE-901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2024
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVE-901 (tramadol) inhibits serotonin reuptake and norepinephrine reuptake, enhancing inhibitory effects on pain transmission in the spinal cord. It is being developed for the treatment of post-operative pain.
Product Name : AVE-901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 25, 2023
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVE-901 (tramadol) inhibits serotonin reuptake and norepinephrine reuptake, enhancing inhibitory effects on pain transmission in the spinal cord. It is being developed for the treatment of post-operative pain.
Product Name : AVE-901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 17, 2023
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Aegis Capital
Deal Size : $12.0 million
Deal Type : Public Offering
Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering
Details : Avenue expects to use the net proceeds from the offering, for general corporate purposes and working capital, including the development of its drug product candidates including AVE-901 (tramadol).
Product Name : AVE-901
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 10, 2022
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Aegis Capital
Deal Size : $12.0 million
Deal Type : Public Offering
Lead Product(s) : Celecoxib,Tramadol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary efficacy endpoint met and studied was summed pain intensity difference from 0 to 48 hours (SPID0-48). SEGLENTIS (celecoxib) had a significantly greater effect on SPID0-48 (least-squares mean: −139.1 than tramadol, celecoxib or placebo.
Product Name : Seglentis
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2022
Lead Product(s) : Celecoxib,Tramadol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Aegis Capital
Deal Size : $12.0 million
Deal Type : Public Offering
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
Details : Avenue expects to use the net proceeds from the offering, for general corporate purposes and working capital, including the development of its drug product candidates including AVE-901 (tramadol).
Product Name : AVE-901
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 10, 2022
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Aegis Capital
Deal Size : $12.0 million
Deal Type : Public Offering
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Aegis Capital
Deal Size : $13.8 million
Deal Type : Public Offering
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
Details : Avenue expects to use the net proceeds to repurchase all of the shares of its common stock held by InvaGen Pharmaceuticals Inc., to be used for general corporate purposes and working capital, including the progression of IV Tramadol (AVE-901) and the dev...
Product Name : AVE-901
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 10, 2022
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Aegis Capital
Deal Size : $13.8 million
Deal Type : Public Offering
Lead Product(s) : Celecoxib,Tramadol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Kowa Pharmaceuticals America
Deal Size : Undisclosed
Deal Type : Agreement
Details :
Product Name : E-58425
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 05, 2021
Lead Product(s) : Celecoxib,Tramadol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Kowa Pharmaceuticals America
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Avenue Therapeutics Provides Regulatory Update for IV Tramadol
Details : Avenue intends to resubmit the NDA in February 2021, barring any Covid-19 related or other setbacks. The NDA resubmission will incorporate revised language relating to the proposed product label and a report relating to terminal sterilization validation.
Product Name : AVE-901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 17, 2020
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Avenue Therapeutics Receives Complete Response Letter from USFDA for IV Tramadol
Details : The CRL stated that IV tramadol, to treat patients in acute pain who require an opioid, is not safe for the intended patient population. If a patient requires an analgesic between the first dose of IV tramadol and the onset of analgesia, a rescue analges...
Product Name : AVE-901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2020
Lead Product(s) : Tramadol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable